ANI Pharmaceuticals
ANIP
Market cap $1.41B

64.96 USD

-1.14

1.72%

At close Jul 11, 4:00 PM EDT

After hours

64.96

+0.00

0.00%

1 day

-1.72%

5 days

-0.34%

1 month

3.47%

3 months

-4.64%

6 months

20.45%

Year to date

17.17%

1 year

1.11%

5 years

132.83%

10 years

-3.32%

About: ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

Employees: 897

Healthcare Drug Manufacturers - Specialty & Generic

0

Funds holding %

of 7,312 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

119% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 21

26% more capital invested

Capital invested by funds: $1.07B [Q4 2024] → $1.35B (+$282M) [Q1 2025]

11% more funds holding

Funds holding: 204 [Q4 2024] → 226 (+22) [Q1 2025]

0.07% more ownership

Funds ownership: 91.71% [Q4 2024] → 91.78% (+0.07%) [Q1 2025]

14% less repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 73

38% less call options, than puts

Call options by funds: $535K | Put options by funds: $863K

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$65

0%

upside

Avg. target

$78

21%

upside

High target

$86

32%

upside

3 analyst ratings

2 positive

67%

1 neutral

33%

0 negative

0%

HC Wainwright & Co. Brandon Folkes	29%upside $84	Buy Initiated	10 Jul 2025
Guggenheim Vamil Divan	32%upside $86	Buy Reiterated	12 May 2025
Truist Securities Gregory Fraser	0%upside $65	Hold Maintained	21 Apr 2025

See Analyst Rankings

Financial journalist opinion

ANI Pharmaceuticals to Participate at Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8th

PRINCETON, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, will host 1x1 meetings at the Leerink Partners Therapeutics Forum: I&I and Metabolism on Tuesday, July 8, 2025, in Boston, MA.

ANI Pharmaceuticals to Participate at Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8th

ANI Pharmaceuticals Announces Presentation of New Preclinical Data

The Use of Purified Cortrophin® Gel in Murine Collagen-Induced Arthritis Mouse Model presented as a poster at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress The Use of Purified Cortrophin® Gel in Murine Collagen-Induced Arthritis Mouse Model presented as a poster at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress

ANI Pharmaceuticals Announces Presentation of New Preclinical Data

ANI Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

PRINCETON, N.J., May 27, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 2025 Jefferies Global Healthcare Conference in New York City as follows:

ANI Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter

ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares

Purified Cortrophin Gel is the only ACTH therapy approved by the FDA for the treatment of acute gout flares Trial to be conducted by Dr. Hyon Choi at Massachusetts General Hospital and will compare the safety and efficacy of two dose levels of Purified Cortrophin Gel for the treatment of acute gout flares PRINCETON, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the initiation of a Phase 4 clinical trial at Massachusetts General Hospital to compare the safety and efficacy of two dose levels (40 USP units and 80 USP units) of Purified Cortrophin Gel (repository corticotropin injection USP) (Cortrophin Gel) for the treatment of acute gout flares.

ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares

ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ

PRINCETON, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ as follows:

ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ

Zacks Investment Research

ANI (ANIP) is an Incredible Growth Stock: 3 Reasons Why

ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.

ANI (ANIP) is an Incredible Growth Stock: 3 Reasons Why

ANI Pharmaceuticals, Inc. (ANIP) Q1 2025 Earnings Call Transcript

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q1 2025 Earnings Conference Call May 9, 2025 8:00 AM ET Company Participants Lisa Wilson - IR, Insight Communications Nikhil Lalwani - President, CEO & Director Christopher Mutz - SVP, Head, Rare Diseases Stephen Carey - CFO & SVP Conference Call Participants Gary Nachman - Raymond James Faisal Khurshid - Leerink Partners Vamil Divan - Guggenheim Securities David Amsellem - Piper Sandler Ekaterina Knyazkova - J.P. Morgan Les Sulewski - Truist Securities Operator Please stand by.

ANI Pharmaceuticals, Inc. (ANIP) Q1 2025 Earnings Call Transcript

Zacks Investment Research

Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?

Here is how ANI Pharmaceuticals (ANIP) and Agenus (AGEN) have performed compared to their sector so far this year.

Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?

Zacks Investment Research

Compared to Estimates, ANI (ANIP) Q1 Earnings: A Look at Key Metrics

The headline numbers for ANI (ANIP) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Compared to Estimates, ANI (ANIP) Q1 Earnings: A Look at Key Metrics

See News Rankings

Charts implemented using Lightweight Charts™